# US 2021/0198341 A1 · Methods of obtaining tumor-specific t cell receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198341 A1
- Document ID: US20210198341A1
- Status: Published application
- Kind: A1
- Application number: 17/047,059
- Filed: 2019-04-12
- Published: 2021-07-01
- Earliest claimed: 2018-04-13
- Assignees: SYZ Cell Therapy Co.; HRYZ (Shenzhen) Biotech Co.
- Applicants: Syz Cell Therapy Co.; Hryz (Shenzhen) Biotech Co.
- Inventors: Xiangjun ZHOU; Yanyan HAN; Xiaoling LIANG; Xihe CHEN
- Web page: https://patentgrep.com/patent/US20210198341A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 39/12: Viral antigens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4201: {Neoantigens}
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4208: {Vascular endothelial growth factor receptors [VEGFR]}
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- A61K 40/4239: {Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR}
- A61K 40/424: {Apoptosis related proteins, e.g. survivin or livin}
- A61K 40/4241: {p53}
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- A61K 40/4246: {Telomerase or [telomerase reverse transcriptase [TERT]}
- A61K 40/4266: {Carcinoembryonic antigen [CEA]}
- A61K 40/4268: {MAGE}
- A61K 40/4269: {NY-ESO}
- A61K 40/46: Viral antigens
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2502/1114: T cells
- C12N 2502/1121: Dendritic cells
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

Provided methods of obtaining a plurality of T cell receptors specifically recognizing a target tumor antigen peptide from an individual that has clinically benefitted from an immunotherapy, such as Multiple Antigen Specific Cell Therapy. Also provided tumor-specific TCRs, engineered immune cells expressing the TCRs and methods of treating a disease using the engineered immune cells.

## Claims

### Claim 1

A method of obtaining a plurality of T cell receptors (TCRs) specifically recognizing a target tumor antigen peptide, comprising:
a) a first co-culturing step comprising co-culturing a first population of dendritic cells (DCs) loaded with the target tumor antigen peptide with a population of T cells from an individual to obtain a first co-culture;
b) an enrichment step comprising subjecting the first co-culture to an enrichment process to obtain enriched activated T cells;
c) a second co-culturing step comprising co-culturing the enriched activated T cells with a second population of DCs loaded with the target tumor antigen peptide to obtain a population of tumor antigen-specific T cells, wherein at least about 10% of the tumor antigen-specific T cells specifically responds to the target tumor antigen peptide; and
d) a sequencing step, comprising subjecting the tumor antigen-specific T cells to next-generation sequencing to identify a plurality of pairs of genes encoding TCRα and TCRβ, thereby providing the plurality of T cell receptors based on paired genes encoding TCRα and TCRβ;
wherein the individual has clinically benefitted from a Multiple Antigen Specific Cell Therapy (MASCT) comprising administering to the individual an effective amount of activated T cells prepared by co-culturing a population of T cells with a population of dendritic cells loaded with a plurality of tumor antigen peptides comprising the target tumor antigen peptide.

### Claim at position 2

2-34. (canceled)

### Claim 35 (depends on 1)

A tumor-specific TCR obtained using the method of claim 1.

### Claim 36

A tumor-specific TCR comprising:
(a) a TCRα chain comprising a complementary determining region (CDR) 3 having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs: 4, 10, and 16; and a TCRβ chain comprising a CDR3 comprising an amino acid sequence having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs: 7, 13, and 19;
(b) a TCRα chain comprising a complementary determining region (CDR) 3 having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs: 22, 28, 34, 40, 46, and 52; and a TCRβ chain comprising a CDR3 comprising an amino acid sequence having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs: 7, 13, 19, 25, 31, 37, 43, 49, and 55; or
(c) a TCRα chain comprising a complementary determining region (CDR) 3 having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs: 58, 64, 70, 76, 87 and 93; and a TCRβ chain comprising a CDR3 comprising an amino acid sequence having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs: 61, 67, 73, 79, 90 and 96.

### Claim 37 (depends on 36)

The tumor-specific TCR of claim 36, comprising:
(a) a TCRα chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 5, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 5, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 4, and a TCRβ chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 8, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 8, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 7;
(b) a TCRα chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 11, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 11, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and a TCRβ chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 14, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 14, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 13; or
(c) a TCRα chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 17, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 17, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 16, and a TCRβ chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 20, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 20, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 19;
(d) a TCRα chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 24, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 24, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 22, and a TCRβ chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 26, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 26, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 25;
(e) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 254, a CDR2 comprising the amino acid sequence of SEQ ID NO: 255, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 28, and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 256, a CDR2 comprising the amino acid sequence of SEQ ID NO: 257, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 31;
(f) a TCRα chain a CDR1 comprising the amino acid sequence of SEQ ID NO: 258, a CDR2 comprising the amino acid sequence of SEQ ID NO: 259, and comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 34, and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 260, a CDR2 comprising the amino acid sequence of SEQ ID NO: 261, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 37;
(g) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 262, a CDR2 comprising the amino acid sequence of SEQ ID NO: 263, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 40, and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 264, a CDR2 comprising the amino acid sequence of SEQ ID NO: 265, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 43;
(h) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 266, a CDR2 comprising the amino acid sequence of SEQ ID NO: 267, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 46, and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 268, a CDR2 comprising the amino acid sequence of SEQ ID NO: 269, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 49; or
(i) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 270, a CDR2 comprising the amino acid sequence of SEQ ID NO: 271, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 52, and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 272, a CDR2 comprising the amino acid sequence of SEQ ID NO: 273, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 55.

### Claim 38

A tumor-specific TCR comprising:
(a) a TCRα chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs: 5, 11 and 17, and a TCRβ chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs: 8, 14 and 20;
(b) a TCRα chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs: 23, 29, 35, 41, 47 and 53, and a TCRβ chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs: 26, 32, 38, 44, 50 and 56; or
(c) a TCRα chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs: 59, 65, 71, 77, 88 and 94, and a TCRβ chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs: 62, 68, 74, 80, 91 and 97.

### Claim 39 (depends on 37)

The tumor-specific TCR of claim 37, comprising:
(a) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 5, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 8;
(b) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 11, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 14;
(c) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 17, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 20;
(d) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 23, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 26;
(e) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 29, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 32;
(f) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 35, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 38;
(g) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 41, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 44;
(h) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 47, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 50; or
(i) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 53, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 56.

### Claim 40 (depends on 36)

An isolated nucleic acid encoding the TCRα chain and/or the TCRβ chain of the tumor-specific TCR of claim 36.

### Claim 41

(canceled)

### Claim 42

An engineered immune cell comprising the tumor-specific TCR of 36.

### Claim 43

(canceled)

### Claim 44 (depends on 42)

A pharmaceutical composition comprising the engineered immune cell of claim 42, and a pharmaceutically acceptable carrier.

### Claim 45 (depends on 44)

A method of treating a cancer in an individual, comprising administering to the individual an effective amount of the pharmaceutical composition of claim 44.

### Claim 46 (depends on 1)

A library of tumor-specific TCRs obtained using the method of claim 1.

### Claim 47 (depends on 36)

The tumor-specific TCR of claim 36, comprising:
(a) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 274, a CDR2 comprising the amino acid sequence of SEQ ID NO: 275, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 58; and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 276, a CDR2 comprising the amino acid sequence of SEQ ID NO: 277, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 61;
(b) a TCRα chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 65, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 65, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 64, and a TCRβ chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO: 68, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO: 68, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 67;
(c) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 278, a CDR2 comprising the amino acid sequence of SEQ ID NO: 279, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 70; and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 280, a CDR2 comprising the amino acid sequence of SEQ ID NO: 281, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 73;
(d) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 282, a CDR2 comprising the amino acid sequence of SEQ ID NO: 283, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 76; and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 284, a CDR2 comprising the amino acid sequence of SEQ ID NO: 285, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 79;
(e) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 286, a CDR2 comprising the amino acid sequence of SEQ ID NO: 287, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 87; and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 288, a CDR2 comprising the amino acid sequence of SEQ ID NO: 289, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or
(f) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 290, a CDR2 comprising the amino acid sequence of SEQ ID NO: 291, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 93; and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 292, a CDR2 comprising the amino acid sequence of SEQ ID NO: 293, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 96.

### Claim 48 (depends on 47)

The tumor-specific TCR of claim 47, comprising:
(a) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 59, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 62;
(b) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 65, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 68;
(c) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 71, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 74;
(d) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 77, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 80;
(e) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 88, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 91; or
(f) a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 94, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 97.

### Claim 49 (depends on 47)

The tumor-specific TCR of claim 47, comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 278, a CDR2 comprising the amino acid sequence of SEQ ID NO: 279, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 70; and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 280, a CDR2 comprising the amino acid sequence of SEQ ID NO: 281, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 73.

### Claim 50 (depends on 48)

The tumor-specific TCR of claim 48, comprising a TCRα chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 71, and a TCRβ chain comprising an amino acid sequence having at least about 80% identity to the amino acid sequence of SEQ ID NO: 74.

### Claim 51 (depends on 49)

An engineered immune cell comprising the tumor-specific TCR of claim 49.

### Claim 52 (depends on 51)

The engineered immune cell of claim 51, wherein the immune cell is a T cell.

### Claim 53 (depends on 52)

A pharmaceutical composition comprising the engineered immune cell of claim 52, and a pharmaceutically acceptable carrier.

### Claim 54 (depends on 53)

A method of treating a cancer in an individual, comprising administering to the individual an effective amount of the pharmaceutical composition of claim 53.
